← All trials
NCT01296256
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- Hospital Morales MeseguerOverall official - principal investigator
- Hospital Jerez de la FronteraOverall official - principal investigator
- University of SantiagoOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
- University of BarcelonaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- Universidad de MurciaOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Badalona Hospital Germans Trias i PujolOverall official - principal investigator
- Universidad Autonoma de BarcelonaOverall official - principal investigator
- Hospital Universitario Central de AsturiasOverall official - principal investigator
- University of Las Palmas de Gran CanariaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.